R. Bryan Rumble

R. Bryan Rumble

Auto-generated profile, based on publicly available information

R. Bryan Rumble

American Society of Clinical Oncology, Alexandria, VA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
WRW. Kimryn Rathmell
W. Kimryn Rathmell
RRR. Bryan Rumble
R. Bryan Rumble
Peter VeldhuizenPeter Veldhuizen
Peter Veldhuizen
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie
HEHamid Emamekhoo
Hamid Emamekhoo
ESEric A. Singer
Eric A. Singer
PURPOSE: To provide recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC).METHODS: An Expert Panel conducted a systematic literature review to obtain evidence to guide treatment recommendations.RESULTS: The panel considered peer-reviewed reports published in English.RECOMMENDATIONS: The diagnosis of metastatic ccRCC should be made using tissue biopsy of the primary tumor or a metastatic site with the inclusion of markers and/or stains to support the diagnosis. The International Metastatic RCC Database Consortium risk criteria should be used to inform treatment. Cytoreductive nephrectomy may be offered to select patients with kidney-in-place and favorable- or intermediate-risk disease. For those who have already had a nephrectomy, an initial period of active surveillance may be offered if they are asymptomatic with a low burden of disease. Patients with favorable-risk disease who need systemic therapy may be offered an immune checkpoint inhibitor (ICI) in combination with a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI); patients with intermediate or poor risk should be offered a doublet regimen (no recommendation was provided between ICIs or an ICI in combination with a VEGFR TKI). For select patients, monotherapy with either an ICI or a VEGFR TKI may be offered on the basis of comorbidities. Interleukin-2 remains an option, although selection criteria could not be identified. Recommendations are also provided for second- and subsequent-line therapy as well as the treatment of bone metastases, brain metastases, or the presence of sarcomatoid features. Participation in clinical trials is highly encouraged for patients with metastatic ccRCC. Additional information is available at www.asco.org/genitourinary-cancer-guidelines

10 July 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RGRohan Garje
Rohan Garje
IRIrbaz Bin Riaz
Irbaz Bin Riaz
SNSyed Arsalan Ahmed Naqvi
Syed Arsalan Ahmed Naqvi
RRR. Bryan Rumble
R. Bryan Rumble
MTMary-Ellen Taplin
Mary-Ellen Taplin
RPRahul A. Parikh
Rahul A. Parikh
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE: To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: An Expert Panel including patient representation completed a systematic review of the evidence and made recommendations. RESULTS: Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic agents (docetaxel, cabazitaxel), radiopharmaceuticals (radium 223, 177 Lu-prostate-specific membrane antigen [PSMA]-617), and sipuleucel-T have demonstrated an overall survival (OS) benefit for patients with mCRPC. For patients with BRCA1 / 2 alterations who did not receive prior ARPI, the combination of PARPi and ARPI (talazoparib + enzalutamide, olaparib and/or niraparib + abiraterone) has shown clinical benefit. For patients with BRCA1 / 2 alterations who received prior ARPI or ARPI followed by docetaxel, olaparib showed OS benefit. In select patients with microsatellite instability-high/mismatch repair-deficient, pembrolizumab showed clinical efficacy. RECOMMENDATIONS: Prior systemic therapy for castration-sensitive prostate cancer will determine subsequent therapy used for mCRPC. Continue androgen-deprivation therapy for patients with mCRPC indefinitely. Early adoption of somatic genetic testing and palliative care is recommended. Patients with mCRPC and bony metastases should receive a bone-protective agent. The panel recommends the combination of ARPI with PARPi in patients with BRCA1 / 2 alterations who did not receive prior ARPI. For patients who received prior ARPI, the panel recommends docetaxel chemotherapy. The panel recommends 177 Lu-PSMA-617 or cabazitaxel chemotherapy for patients who receive prior ARPI and docetaxel chemotherapy. For patients with BRCA1 / 2 alterations who received prior ARPI, the panel recommends PARPi monotherapy. Radium 223 is recommended for patients with symptomatic bone–only disease. Evidence for optimal sequencing for mCRPC regimens is lacking. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .

20 February 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EYEvan Y. Yu
Evan Y. Yu
RRR. Bryan Rumble
R. Bryan Rumble
NANeeraj Agarwal
Neeraj Agarwal
HCHeather H. Cheng
Heather H. Cheng
SEScott E. Eggener
Scott E. Eggener
ETEdouard Trabulsi
Edouard Trabulsi
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE: To evaluate evidence on germline and somatic genomic testing for patients with metastatic prostate cancer and provide recommendations. METHODS: A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2018 to May 2024. Articles were selected for inclusion if they reported on patients with metastatic prostate cancer who received a germline or somatic genomic test and/or made comparisons between those tests, reported detection rates, prognostic information, or treatment implications. RESULTS: A total of 1,713 papers were identified in the literature search. After applying the eligibility criteria, 14 remained: eight systematic reviews and six clinical trials. RECOMMENDATIONS: Patients with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays. These tests can guide the use of poly(ADP-ribose) polymerase inhibitors, which have a survival benefit in metastatic castration-resistant prostate cancer. In addition, germline testing may have screening implications for additional cancers for patients and cascade testing implications for family members. The data supporting when to perform repeat testing and optimal tissue type to use (eg, primary tumor v metastatic biopsy versus circulating tumor DNA [ctDNA] testing) are more limited, but this panel recommends considering retesting in patients whose results were previously negative or uninformative, and to consider either a metastatic biopsy or ctDNA when a significant change in clinical status occurs. Next-generation genomic sequencing findings that are associated with prognostic only (and not predictive) value should not be used to guide treatment outside of a clinical trial. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .

10 July 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KVKatherine S. Virgo
Katherine S. Virgo
RRR. Bryan Rumble
R. Bryan Rumble
JTJames Talcott
James Talcott

20 February 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BMBeverly Moy
Beverly Moy
RRR. Bryan Rumble
R. Bryan Rumble
LCLisa A. Anne Carey
Lisa A. Anne Carey
FCFor The Chemotherapy
For The Chemotherapy
TPTargeted Therapy For Endocrine-Pretreated Or Hormone Receptor–Negative Metastatic Breast Cancer Expert Panel
Targeted Therapy For Endocrine-Pretreated Or Hormone Receptor–Negative Metastatic Breast Cancer Expert Panel
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.

10 September 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BMBeverly Moy
Beverly Moy
RRR. Bryan Rumble
R. Bryan Rumble
LCLisa A. Anne Carey
Lisa A. Anne Carey
FCFor The Chemotherapy
For The Chemotherapy
TPTargeted Therapy For Her2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated Or Hormone Receptor–Negative Expert Panel
Targeted Therapy For Her2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated Or Hormone Receptor–Negative Expert Panel
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.